Kenvue Inc. (KVUE) Stock Price & How to Invest

Kenvue is the world's largest pure-play consumer health company, spun off from Johnson & Johnson in 2023. It owns a portfolio of iconic over-the-counter and personal-care brands organized into three segments: Self Care (Tylenol, Motrin, Sudafed, Zyrtec, Benadryl, Nicorette, Imodium), Skin Health and Beauty (Neutrogena, Aveeno, OGX), and Essential Health (Listerine, Band-Aid, Johnson's baby products, Aveeno). Kenvue sells everyday, repeat-purchase health and hygiene products through pharmacies, mass retailers, grocery, and e-commerce in markets around the world. The business makes money by leveraging strong, trusted brands and broad retail distribution to command premium pricing over private label in non-discretionary categories like pain relief, allergy care, oral care, and wound care. Many of its products are recommended by doctors and pharmacists, which reinforces brand loyalty. As a recently independent company, Kenvue is still building out standalone operations and pursuing cost efficiencies, while navigating litigation it inherited from its J&J consumer heritage. Headquartered in Summit, New Jersey.

Kenvue carries significant litigation overhang inherited from its J&J heritage, including high-profile Tylenol and talc-related claims, which create legal and headline risk. As a young standalone company it is still proving it can execute independently and grow organically, and early results have shown uneven volume trends. Private-label competition pressures pricing in OTC and personal care, input-cost inflation hits margins, and heavy international exposure adds currency risk. Activist pressure and possible portfolio changes add uncertainty, and slow growth makes the stock sensitive to interest rates and consumer trade-down.

12 analysts publish price targets on KVUE, averaging $19.83 against a $19.66 price as of July 2026, or +0.9%. The published targets run from $18.00 to $23.00, a narrow spread, and the ratings split 2 buy, 12 hold, 0 sell. Over the last six months there have been 5 raises and 3 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full KVUE forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Kenvue Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Portfolio of trusted, defensive brands. Kenvue owns category-leading names like Tylenol, Listerine, Neutrogena, Band-Aid, and Aveeno, many recommended by doctors and pharmacists. The most optimistic published target, $23.00, assumes this works close to its best case.

The case against. Kenvue carries significant litigation overhang inherited from its J&J heritage, including high-profile Tylenol and talc-related claims, which create legal and headline risk. The most pessimistic target, $18.00, is roughly what KVUE is worth if this bites instead.

Read the full bull and bear case on KVUE, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Kenvue Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$15 billion
• Operating margin: ~18%
• Net income (TTM): ~$1.5 billion
• P/E (TTM): ~20x
• Dividend yield: ~4%
• Free cash flow: ~$2 billion annually
• Spin-off date: 2023 (separated from Johnson & Johnson)

Kenvue trades at a consumer-staples multiple, somewhat below larger, faster-growing peers, reflecting its strong brands offset by litigation overhang and an unproven standalone growth track record. The above-average dividend yield is a key anchor for income investors. The valuation embeds expectations of margin improvement and steadier organic growth as the company matures independently and resolves legal uncertainties.

Other names that sit close to KVUE: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get KVUE exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so KVUE sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where KVUE fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Kenvue (KVUE) is a young standalone owner of trusted, repeat-purchase OTC and personal-care brands, with margin-improvement potential offset by an unproven independent growth record and J&J-era legal claims. In a portfolio it behaves as a defensive, high-yield staples holding whose roughly 4% dividend is the main anchor, carrying litigation risk as a noted caveat.

Whether KVUE is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is KVUE a buy or a sell?, and where the stock could go from here in the KVUE stock forecast.

For income investors, whether KVUE pays a dividend and how the payout looks is covered in does KVUE pay a dividend? And to weigh KVUE against a peer, read the full side-by-side comparisons: KVUE vs HLN and KVUE vs PG.